Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.
about
Potential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome BrainDifferential biological activity of disease-associated JAK2 mutantsJAK and MPL mutations in myeloid malignancies.Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.The Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009.The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.Activation of JAK2-V617F by components of heterodimeric cytokine receptorsc-Abl activates janus kinase 2 in normal hematopoietic cells.Investigation and analysis of single nucleotide polymorphisms in Janus kinase/signal transducer and activator of transcription genes with leukemia.Association of Janus kinase 2 (JAK2) polymorphisms with acute leukemia susceptibility.Down syndrome--recent progress and future prospects.Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesUnderstanding the biology of CRLF2-overexpressing acute lymphoblastic leukemiaComparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disordersUpdate on JAK2 Inhibitors in Myeloproliferative NeoplasmDown syndrome and the molecular pathogenesis resulting from trisomy of human chromosome 21.Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth.Constitutional aneuploidy and cancer predisposition.Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndromeJAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model.Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activationHigh CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement.A comparison of acute lymphoblastic leukemia in Down syndrome and non-Down syndrome children: the role of trisomy 21.Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinasesGenomic profiling of high-risk acute lymphoblastic leukemia.Pseudokinases-remnants of evolution or key allosteric regulators?Unique clinical and biological features of leukemia in Down syndrome children.PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms.A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.JAK2 inhibition for the treatment of hematologic and solid malignancies.Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia.Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.Thymic stromal lymphopoietin and cancer.A Novel Homozygous Nucleotide Deletion in the JAK2 Gene in a Pediatric Patient with B-cell Precursor Acute Lymphoblastic Leukemia
P2860
Q26765647-3E37A49F-6683-4D6D-B7E3-6B70D97D6137Q28508045-069A5E6B-BF23-4A9A-A03F-6A9928759DD5Q33378737-1771D637-8846-40BF-A147-A53CF69AAD4AQ33586552-4AA18FB8-E0EA-405E-A53D-89E355CCF36EQ33591867-69BBA4D3-BF47-42D5-9A6E-F4B9FAC3931BQ33636082-78BBD8E5-64D9-4809-8E34-0E58FD860A7FQ33698398-339DF94F-BB6F-4D53-B612-D12A20CE2129Q33883366-DFD6A87F-C8A5-4A11-8F50-71E838BE78F0Q33985308-8933D3C5-FB56-43FF-90A3-11173CC57C3CQ34085965-849BA0A5-1E8B-4577-997F-59EB456978ECQ34100823-BE967B7C-7D18-4C86-89FD-9F1750FC2C3AQ34964947-B1185ED8-C343-43ED-9CA1-BF03EBA4FE75Q35132241-6BF7FC24-713C-4408-90A6-46F3AC1733DCQ35500533-AB2FE152-1AAA-4158-85E6-3890DC4C93B7Q36374813-C5B7D9C6-B6B0-4A56-8299-7F96DEB8D060Q36612569-933FDE07-DD2D-4E88-B6BC-30DEC7DDE13DQ36681400-DDB0D6CF-5560-4F4F-A7E5-1FCD4B420EA9Q36963919-5AFA5152-17F5-4B0E-9E54-391AA0F48960Q37134129-9AFB4343-2484-435B-8458-13A633F3FFEAQ37142140-2B80E601-1312-42D7-A1ED-B1BBBE2AD89DQ37255016-72C06F64-170C-49CA-A197-78AE1B7FB265Q37273194-7C7BAB69-4D40-4934-822B-FC6F7E14BF07Q37300183-9E821016-4A96-4AC9-8F0F-C59D5AF5862EQ37379320-A5B0A67B-80F3-4054-A497-1D2B7066369AQ37446881-153EA093-9699-40D6-9003-C57F36A27265Q37580303-ABDAA511-B042-42FE-9011-6C8EA55A422AQ37661998-A8D728FF-118E-460A-AD51-EA277531DE42Q37687519-F2D9DC89-A50D-4C7C-B6B8-8EB94FE7A80AQ37782546-13C74693-AE8E-43B6-9ED6-85FD3C314650Q37809200-E5E6DFC7-BBE2-4A10-86C1-AA5D8A1142AAQ37810271-50A58B0F-FBFC-4A36-8FB4-E31830536119Q37810947-886E292F-0B21-4D9F-BB62-9CEDC0746F56Q37921836-6275F539-5A21-4B2C-903F-59B567F695BBQ38001733-6F663E2F-C39F-4BE0-A383-AF0A74726519Q38102578-3D12FD1F-2545-42FB-9095-75B68BB9664AQ38122238-DF255B02-CCCB-4FE1-BD37-67B13F637C57Q38132817-8848646C-81F9-47EE-A518-B209ED1C74D6Q38164139-62C4FCF8-D822-4E93-8E83-A654B08E6023Q38261183-B2BC707D-3E3B-4ABF-A76D-C8A28D3E4872Q38757062-8798F59E-FF05-4442-9335-01F9621BC2A2
P2860
Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Novel activating JAK2 mutation ...... acute lymphoblastic leukemia.
@en
type
label
Novel activating JAK2 mutation ...... acute lymphoblastic leukemia.
@en
prefLabel
Novel activating JAK2 mutation ...... acute lymphoblastic leukemia.
@en
P2093
P50
P1433
P1476
Novel activating JAK2 mutation ...... r acute lymphoblastic leukemia
@en
P2093
Catherine Settegrana
Elizabeth A Macintyre
Isabelle Radford-Weiss
Kheira Beldjord
Marianne Debre
Raouf Ben-Abdelali
Roland Berger
Sebastien Malinge
P304
P356
10.1182/BLOOD-2006-09-045963
P407
P577
2006-10-26T00:00:00Z